 The study is a two centre, open-label, uncontrolled single group phase 1A study of C19-A3 GNP peptide 10 μg peptide equivalent content administered via Nanopass microneedles every 28 days for 8 weeks 3 doses, with follow-up for 6 weeks 14 weeks in total from first dose. Treatment will be given into the arm at a volume of 50ul. 